Repurposing of drugs against bacterial infections: A pharmacovigilance‐based data mining approach

Abstract The World Health Organization (WHO) has published a list of priority pathogens that urgently require research to develop new antibiotics. The main aim of the current study is to identify potential marketed drugs that can be repurposed against bacterial infections. A pharmacovigilance‐based drug repurposing approach was used to identify potential drugs. OpenVigil 2.1 tool was used to query the FDA Adverse Event Reporting System database. The reporting odds ratio (ROR) < 1, ROR95CI upper bound <1, and no. of cases ≥30 were used for filtering and sorting of drugs. Sunburst plot was used to represent drugs in a hierarchical order using the Anatomical Therapeutic Chemical classification. Molecular docking and dynamics were performed using the Maestro and Desmond modules of Schrodinger 2023 software respectively. A total of 40 drugs with different classes were identified based on the pharmacovigilance approach which has antibacterial potential. The molecular docking results have shown energetically favored binding conformation of lisinopril against 3‐deoxy‐manno‐octulosonate cytidylyltransferase, UDP‐2,3‐diacylglucosamine hydrolase, and penicillin‐binding protein 3 (PBP3) of Pseudomonas aeruginosa ; olmesartan, atorvastatin against lipoteichoic acids flippase LtaA and rosiglitazone and varenicline against d ‐alanine ligase of Staphylococcus aureus ; valsartan against peptidoglycan deacetylase (SpPgdA) and atorvastatin against CDP‐activated ribitol for teichoic acid precursors of Streptococcus pneumoniae . Further, molecular dynamic results have shown the stability of identified drugs in the active site of bacterial targets except lisinopril with PBP3. Lisinopril, olmesartan, atorvastatin, rosiglitazone, varenicline, and valsartan have been identified as potential drugs for repurposing against bacterial infection.